19-05-2025
Boehringer Banks on New Lung Fibrosis Drug Being a Game Changer
Germany's Boehringer Ingelheim GmbH filed with regulators in the US, China and Europe to sell a new treatment for lung fibrosis, marking progress for a disease that kills many patients within five years.
The experimental treatment, called nerandomilast, slowed lung-function decline in patients with two forms of organ scarring in a pair of advanced studies, the company said Monday.
